

ABSTRACT

The present invention relates to amino-terminally truncated MCP-2, lacking NH₂-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as 5 cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.